PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
|
|
- Cecil Cunningham
- 5 years ago
- Views:
Transcription
1 PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE TA Guidance Reduce prescribing of unnecessary hypnotic medication 2. Reduce duration of prescribing of hypnotic medication 3. Increase awareness of sleep hygiene measures All staff involved in prescribing, dispensing, distributing and administering medication DATE APPROVED 7 th December 2017 VERSION NUMBER 3.0 APPROVING COMMITTEE Executive Board DATE OF IMPLEMENTATION 5 th January 2018 DATE OF FORMAL REVIEW December 2020 AUTHOR/REVIEWER: RESPONSIBLE DIRECTORATE DISTRIBUTION Medicines Management Committee Medical Directorate All staff involved in prescribing, dispensing, distributing and administering medication This policy has been reviewed and is compliant with the most up to date Code of Practice and NICE Guidelines TITLE OF CODE OF PRACTICE NICE REFERENCE NUMBER TA77 Page 1 of 7
2 VERSION CONTROL SHEET Version Date Author Status Comment 1 7/07/10 Fiona Approved /01/16 Fiona Draft /01/16 Fiona Approved 2.1 June 2017 Fiona Draft 3.0 December 2017 Fiona Approved Page/Paragraph/ Appendix Number (select the appropriate action) Summary of Changes since Version 2 Original / New / Amendment / Deleted Statement (select the appropriate action) 3.11 Within the Trust, zolpidem is the current hypnotic of choice. Amendment 3.12 Prescribers are reminded that the maximum licensed dose of zopiclone for an adult is 7.5mg or mg at night for older adults. Deleted 3.13 There is evidence that benzodiazepines with a shorter half-life e.g. lorazepam have a higher dependence potential than longer acting agents e.g. diazepam. Deleted 4.0 REFERENCES NICE TA Guidance : Zaleplon, zolpidem and zopiclone for the short-term management of insomnia Deleted 4.0 New 5.0 New 6.0 New 7.0 New Page 2 of 7
3 HYPNOTIC MEDICATION GUIDELINES 1.0 INTRODUCTION 1.1 The aim of these guidelines is to ensure that benzodiazepines and other hypnotic drugs (e.g. the Z-hypnotics zopiclone, zaleplon and zolpidem) are prescribed appropriately and reviewed regularly to prevent dependence and withdrawal problems. 1.2 Dependence, (physical and psychological) and tolerance can occur if these drugs are taken regularly for more than a few weeks and this may lead to difficulty in stopping the drug. 1.3 They should be reserved for short courses to alleviate severe, disabling symptoms. 1.4 Chronic insomnia is rarely benefited by long-term prescribing of these medications. 1.5 The Committee of Safety of Medicines issues the following advice: Benzodiazepines should be used to treat insomnia only when it is severe, disabling, or subjecting the individual to extreme distress. 1.6 The Z-hypnotics are not licensed for long-term use and are now known to have similar dependence problems. 2.0 RELATED POLICY The Medicines Policy 3.0 GUIDELINES 3.1 Exploring sleep difficulties should be an integral part of the patient history taking process. 3.2 Prior to initiating pharmacological treatment, consideration should be given to: Other mental health diagnoses e.g. acute mania, which should be treated appropriately. Page 3 of 7
4 Sleep hygiene measures (see Appendix 1) e.g. address excessive caffeine intake, being mindful of related issues such as caffeine withdrawal symptoms and changes in plasma levels of concomitant medication such as clozapine. Other medication that may cause insomnia e.g. SSRIs and procyclidine administered at night. 3.3 Clinicians should be aware if, and for how long a patient has been on hypnotics and whether they are being taken regularly or intermittently. 3.4 After taking the clinical picture into consideration, stopping the hypnotic may be an option: If a patient has been taking the hypnotic for longer than four weeks it should not be stopped abruptly as this may precipitate withdrawal symptoms. Discontinuation should be planned and gradual over at least 4-6 weeks (longer in some cases). 3.5 It should be documented in the notes that the above issues have been discussed before prescribing any hypnotics. 3.6 When prescribing hypnotics: Keep in strict accordance with their licensed indications. Limit the prescription initially to no more than 7 days then review. Set down a clear indication in the patient s notes for prescribing with an appropriate review date. State the review/stop date clearly on the prescription card. Consider intermittent use (every 2 nd /3 rd night) to help prevent tolerance developing. Switching from one to another should only occur if a patient experiences adverse effects directly related to a specific agent. Patients who have not responded to one agent should not be prescribed any of the other treatments that act at the benzodiazepine receptor. Do not write up PRN (as required) prescriptions of hypnotics for all patients on admission in case they may be required at a later time. (See Medicines Guideline: PRN Medication in In-patient Settings) 3.7 There may be exceptional cases where patients with severely disabling symptoms are prescribed longer courses of hypnotics under the supervision of a consultant. Page 4 of 7
5 3.8 Specific risks should be taken into consideration e.g. diversion, addiction and overdose in susceptible patient groups. 3.9 The suitability of benzodiazepines, especially long-acting, should be taken into consideration in certain patient groups, e.g. older adults, patients with hepatic impairment At discharge, all hypnotic prescriptions should be reviewed, especially where they have been initiated during a hospital admission Within the Trust, zolpidem is the current hypnotic of choice Clinical teams should regularly audit their prescribing of benzodiazepines and other hypnotic drugs. 4.0 PRESCRIBING INFORMATION FOR ZOLPIDEM 4.1 Dose: 10mg ON; maximum 4 weeks duration Elderly, 5mg ON Hepatic impairment, 5mg ON 4.2 Precautions: Combination with CNS depressants: Enhancement of the central depressive effect may occur in cases of concomitant use with antipsychotics), hypnotics, anxiolytics/sedatives, antidepressant agents, narcotic analgesics, antiepileptic drugs, anaesthetics and sedative antihistamines. Concomitant use of zolpidem with these drugs may increase drowsiness and next-day psychomotor impairment, including impaired driving ability. CYP450 inhibitors and inducers: Co-administration of ciprofloxacin may increase blood levels of zolpidem tartrate, concurrent use is not recommended. Since CYP3A4 plays an important role in zolpidem tartrate metabolism, possible interactions with drugs that are substrates or inducers of CYP3A4 should be considered. Page 5 of 7
6 5.0 RISKS ASSOCIATED WITH HYPNOTICS Falls Cognitive impairment Dependence Withdrawal symptoms Increased risk of dementia Impaired ability to drive 6.0 DRUGS AND DRIVING 6.1 A new offence of driving with certain controlled drugs above specified limits in the blood came into force in March Prescription drugs covered by the new offence include amfetamine, clonazepam, diazepam, flunitrazepam, lorazepam, methadone, morphine or opioid-based drugs, oxazepam and temazepam. 6.2 The risk of next-day psychomotor impairment, including impaired driving ability, is increased if zolpidem tartrate is taken within less than 8 hours before performing activities that require mental alertness. 7.0 REFERENCES NICE TA Guidance : Zaleplon, zolpidem and zopiclone for the short-term management of insomnia SPC: Stilnoct 10mg tablets NICE advice: Hypnotics 15 Jan 2015 KTT6 Page 6 of 7
7 Appendix 1 Having Trouble Sleeping Leaflet Page 7 of 7
Benzodiazepines and Hypnotics
Benzodiazepines and Hypnotics Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date):
More informationMMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA
MMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA Page 1 of 11 Table of Contents Why we need this Guideline... 3 What the Policy is trying to do... 3 Which stakeholders have been
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationPROCEDURE: SABP/EXECUTIVE BOARD/0017/PROCEDURE 11. Administration
PROCEDURE: SABP/EXECUTIVE BOARD/0017/PROCEDURE 11 NAME OF PROCEDURE: REASON FOR THE PROCEDURE: WHAT THE PROCEDURE WILL ACHIEVE: Medicines Procedure: Homely Remedies Administration Guidance on administration
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationFriend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationThe Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability
The Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability Danielle Adams Principal Clinical Pharmacist Pharmacy and Medicines Optimisation Team HPFT July 2017 1
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationBenzodiazepines: risks, benefits or dependence
Benzodiazepines: risks, benefits or dependence A re-evaluation Council Report CR 59 January 1997 Royal College of Psychiatrists, London Due for review: January 2002 1 Contents A College Statement 3 Benefits
More informationInsomnia Management Guideline
Insomnia Management Guideline Guideline Development This document is an update of existing guidance and has been developed by Barnsley CCG Medicines Management Team in consultation with colleagues from
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationSafe Prescribing and Dispensing of Controlled Drugs. Joint Guidance Medical Council and Pharmaceutical Society of Ireland
Safe Prescribing and Dispensing of Controlled Drugs Joint Guidance Medical Council and Pharmaceutical Society of Ireland Purpose of this Guidance Purpose of this Guidance This resource aims to facilitate
More informationA Pharmacist s Guide to Intermezzo
A Pharmacist s Guide to Intermezzo Intermezzo (zolpidem tartrate) is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to
More informationPROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE
PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE BRIEF OUTLINE OF THIS PROCEDURE This procedure sets out the requirements for prescribing,
More informationGuidance For NHS Grampian Clinicians On The Management Of Insomnia And The Use Of Hypnotics
Guidance For NHS Grampian Clinicians On The Management Of Insomnia And The Use Of Hypnotics Co-ordinators: Specialist Pharmacists in Substance Misuse Reviewer: Bruce Davidson Consultant Psychiatrist and
More informationAnxiolytic and Hypnotic drugs
Anxiolytic and Hypnotic drugs Anxiolytic and Hypnotic drugs Anxiety is unpleasant state of tension and fear that seems to arise from unknown source. The symptoms of severe anxiety are similar to those
More informationOregon s PDMP: An epidemiological assist tool
Oregon s PDMP: An epidemiological assist tool Todd Beran Center for Prevention and Health Promotion Oregon Health Authority PDMP TTAC Webinar February 13, 2013 1 Acknowledgements Lisa Millet, MSH, Section
More informationVI.2 Elements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Zolpidem is used for short-term treatment of serious sleep problems that incapacitate or cause people extreme distress. Zolpidem
More information1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)
Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer
More informationReduction in the Use of Night Sedation to Reduce the Risk of Falls
Reduction in the Use of Night Sedation to Reduce the Risk of Falls Ms Margaret Hargraves Hospital Pharmacist Prince of Wales Hospital South Eastern Sydney Illawarra Area Health Service Objectives Falls
More informationHigh Risk Medicines Prescribing Policy. July 2017
High Risk Medicines Prescribing Policy July 2017 Responsible Committee: Quality Committee Date Effective: July 2017 Author: Rahinatu Amadu Supersedes: July 2016 Next Review Due: July 2018 1. INTRODUCTION
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update 1 Guideline title Anxiety: management of generalised anxiety disorder in adults in primary, secondary and community care (update)
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationMELATONIN Information for Primary Care
North of Tyne Area Prescribing Committee Shared Care Group MELATONIN Information for Primary Care Background Melatonin is a hormone secreted by the pineal gland. It is normally secreted at night and its
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationSEDATIVE-HYPNOTIC AGENTS
SEDATIVE-HYPNOTIC AGENTS Documentation A. FDA approved indications 1. Insomnia 2. Sedation for an agitated patient in an inpatient setting Documentation B. Non-FDA approved, commonly used indications 1.
More informationRevised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017
Revised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017 A. Application of Guidelines Guidelines on Proper Prescription
More informationhypnotics and anxiolytics
hypnotics and anxiolytics Hypnotics and anxiolytics Most hypnotics and anxiolytics prescribed in Luxemburg are benzodiazepines and similar medications, such as Z-drugs (see table page 4). Legal status
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationBenzodiazepines. Benzodiazepines
: History 1950s - Invented by Swiss chemists who identified its sedative effects 1950s 60s - Chlordiazepoxide (Librium) marketed as a safer alternative to barbiturates; along with newer benzodiazepines
More informationStilnoct 10mg Tablets: White to off-white film-coated oblong tablet, scored and engraved SN 10 on one side, containing 10mg zolpidem tartrate.
1. NAME OF THE MEDICINAL PRODUCT Stilnoct 5mg Stilnoct 10mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Stilnoct 5mg Tablets: Round white film coated tablets containing 5mg zolpidem tartrate. Stilnoct
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationCan you take sleeping pills with ativan
Cari untuk: Cari Cari Can you take sleeping pills with ativan 30-5-2015 Can 't sleep? Consumer Reports Best Buy Drugs explains why the Best Insomnia Treatment Is Not A Drug. 2-3-2018 Sleeping Pills: What
More informationBenzodiazepines: Comparative Effectiveness and Strategies for Discontinuation. Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project
Benzodiazepines: Comparative Effectiveness and Strategies for Discontinuation Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project This project is funded through a grant from the Pew Charitable
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationGuidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act
Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act This guidance is intended for Coventry and Warwickshire Partnership Trust staff to use when
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationPharmacological Help for a Good Night s s Sleep. Thomas Owens, MD
Pharmacological Help for a Good Night s s Sleep Thomas Owens, MD Objectives 1. Define insomnia and characterize the symptoms and array of causes. 2. Describe traditional and new pharmacologic approaches
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More information11/1/2010. Psychology 472 Pharmacology of Psychoactive Drugs. Listen to the audio lecture while viewing these slides
Treatment for Anxiety Disorders Benzodiazepines and Other Anxiolytics Psychology 472 Pharmacology of Psychoactive Drugs Listen to the audio lecture while viewing these slides Ethanol Barbiturates and related
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Stilnoct 10mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Zolpidem tartrate 10mg Excipients:
More informationThe Medical Letter. on Drugs and Therapeutics. Usual Adult Hypnotic Dose 1,2 Some Adverse Effects Comments Cost 3
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services DRIVING AND MENTAL HEALTH CONDITIONS AND TREATMENTS General information Driving while impaired by a physical
More informationPackage leaflet: Information for the user. Zolpidem Vitabalans 10 mg film-coated tablets zolpidem tartrate
Package leaflet: Information for the user Zolpidem Vitabalans 10 mg film-coated tablets zolpidem tartrate Read all of this leaflet carefully before you start using this medicine because it contains important
More informationMedicines Optimisation Strategy
Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT STILNOCT 10mg/ZOLPIDEM TARTRATE 10MG TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Stilnoct 10mg Tablets: White to off-white film-coated
More informationAnswer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.
CLINICAL THERAPEUTICS 7: PSYCHIATRY PHA-MHBY Time allowed: 2 hours UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-2014 Part ONE Answer ALL questions. For each question, there
More informationOpioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older
Opioid Prescribing for Acute Pain Care for People 15 Years of Age and Older Summary This quality standard provides guidance on the appropriate prescribing, monitoring, and tapering of opioids to treat
More informationWhat is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration
What is pregabalin? Pregabalin is a prescription drug used to manage a number of long-term conditions, including epilepsy, neuropathic pain and generalised anxiety disorder. Similar to benzodiazepines,
More informationRamelteon to ambien The Borg System is 100 % Retrievable & Reusable Ramelteon to ambien
Ramelteon to ambien The Borg System is 100 % Ramelteon to ambien Learn about how ROZEREM (ramelteon ) works, its side effects, and clinical studies in adults and older patients. See Important Safety Information
More informationValdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals
Important information Do not discard! Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults Prescriber Guide Information for Healthcare Professionals Recommendations regarding:
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationDr Chris Ford Clinical Director IDHDP (International Doctors for Healthy Drug Policies) Thursday 16 th May 2013
Dr Chris Ford Clinical Director IDHDP (International Doctors for Healthy Drug Policies) Thursday 16 th May 2013 The Beginning Benzodiazepines always a problem Most loved Addiction 2004 Jaffe et al Not
More informationDRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS
DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS DR IÑIGO PEREZ MEDICAL ADVISER, DVLA GENERAL PRACTICE HOT TOPICS NOTTINGHAM 22 APRIL 2017 OUTLINE Drug driving Epilepsy concessions Fit to drive DRUG DRIVING
More informationIntroduction to psychotropic medications JAYNE CAMPBELL
Introduction to psychotropic medications JAYNE CAMPBELL Introduction Psychotropic medications are prescription drugs that are commonly used to control some symptoms associated with many different types
More informationSafe transfer of prescribing guidance
Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationGuidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Guidance on the use of zaleplon, zolpidem and zopiclone for the Issued: April 2004 guidance.nice.org.uk/ta77 NICE 2004 Contents 1 Guidance... 3 2 Clinical need and practice... 4 3 The technologies... 8
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationAddressing the Multiple Causes and Lifestyle Impacts of Insomnia: A Guide for Patient Counseling
Addressing the Multiple Causes and Lifestyle Impacts of Insomnia: A Guide for Patient Counseling Educational Objectives: At the completion of this knowledge-based activity, participants will be able to:
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationStrategies in Managing Opioid and Benzodiazepine Co-Prescribing
Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Scott Endsley, MD Associate Medical Director, Quality Partnership HealthPlan of California October 25, 2016 Audio Instructions To avoid echoes
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG
More informationZopiclone stay in system
Zopiclone stay in system Zopiclone how long does it stay in the system. If i only take one zopiclone 7 5 one night a week how many hours will it stay in my system before it has completely. GO How long
More informationAlcohol Detoxification (Inpatient) Prescribing Guidelines
Alcohol Detoxification (Inpatient) Prescribing Guidelines Author: Sponsor/Executive: Responsible committee: Consultation & Approval: (Committee/Groups which signed off the procedure, including date) This
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationYou May Be at Risk. You are currently taking a sedative-hypnotic drug. Please Bring This Information With You To Your Next Medical Appointment
You are currently taking a sedative-hypnotic drug Alprazolam Chlordiazepoxide Clonazepam Diazepam Estazolam Flurazepam Lorazepam Oxazepam Temazepam Triazolam Eszopiclone Zaleplon Zolpidem Please Bring
More informationAnalgesics: Management of Pain In the Elderly Handout Package
Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed
More information1. Carrying Personal Medications into Thailand A. Medications containing narcotic drugs of category 2
Guidance for Travellers to Thailand under Treatment Carrying Personal Medications Containing Narcotic Drugs/Psychotropic Substances into/out of Thailand This guidance issued by the Narcotics Control Division,
More informationZOPICLONE Product Monograph Page 34 of 38
PART III: CONSUMER INFORMATION Pr ZOPICLONE Zopiclone Tablets 5 mg and 7.5 mg House Standard This leaflet is part III of a three-part "Product Monograph" published when ZOPICLONE was approved for sale
More informationDriving and Pain. Guidance for Faculty of Pain Medicine Members
Driving and Pain Guidance for Faculty of Pain Medicine Members Introduction Road traffic accidents remain a significant public health problem in the UK. In 2016 there were over 180,000 casualties resulting
More informationYou May Be at Risk. You are taking one of the following sedative-hypnotic medications:
You May Be at Risk You are taking one of the following sedative-hypnotic medications: Alprazolam (Xanax ) Bromazepam (Lectopam ) Chlorazepate Chlordiazepoxideamitriptyline Clidinium-chlordiazepoxide Clobazam
More informationRELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH
RELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationProtocol For: Personally Furnishing Naloxone. Update Log
Protocol For: Personally Furnishing Naloxone Update Log Updated By: Reason for Update: Date: Approved By: K. Benick RN Original draft 6/7/16 Pam Butler Protocol: Personally Furnishing Naloxone_Morrow County
More informationFalls most commonly seen in RACFs are due to tripping, slipping and stumbling (21.6%). Falling down stairs is relatively uncommon in
This Presentation Medications and Falls Dr Peter Tenni M Pharm (Curtin), PhD (UTAS) AACPA Director, CPS A fall is an event which results in a person coming to rest inadvertently on the ground or floor
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More informationGreater Manchester Interface Prescribing Group Shared Care Guideline
Greater Manchester Interface Prescribing Group Shared Care Guideline Shared Care Guideline for Melatonin Circadin Author(s)/Originator(s): Dr Rob Rifkin Paediatrician RI Adele Gothard Paediatric Pharmacist
More informationEU Core Safety Profile
EU Core Safety Profile Active Substance: Triazolam Brand Names: HALCION, SOMESE Pharmaceutical form(s)/strength: Tablets RMS: Finland Date: 9 th Dec 2013 Supersedes: 24 th May 2010 4.3. Contraindications
More informationADULT PRIMARY INSOMNIA
Clinical Practice Guideline Adult Primary Insomnia: Diagnosis to Management 2007 Update This guideline was developed by a Clinical Practice Guidelines Working Group to assist physicians in the management
More informationZolpidemtartraat 10 mg, filmomhulde tabletten MODULE package leaflet 2006/09 Clean version PACKAGE LEAFLET: INFORMATION FOR THE USER
Procedure No: NL/H/0272/01/II/009 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Zolpidemtartraat 10 mg, filmcoated tablets Zolpidem tartrate Read all of this leaflet carefully before you start taking this
More informationGUIDELINES FOR THE USE OF BENZODIAZEPINES IN OFFICE PRACTICE IN THE STATE OF MAINE
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 GUIDELINES FOR THE USE OF BENZODIAZEPINES IN OFFICE PRACTICE IN THE STATE OF MAINE Introduction:
More informationMENTAL HEALTH SERVICES 2010 MEDICATION
MENTAL HEALTH SERVICES 2010 INTRODUCTION MEDICATION Under the Mental Health Act 2001 the Inspectorate carries out a review of mental health services in the state and furnishes a report on the quality of
More informationSleep, oil on canvas, 1937, Salvador Dali.
LORAZEPAM Sleep, oil on canvas, 1937, Salvador Dali. I have often imagined the monster of sleep as a heavy, giant head with a tapering body held up by the crutches of reality. When the crutches break we
More informationDrugs used to relieve behavioural and psychological symptoms in dementia
alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,
More informationMMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION
MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION Page 1 of 13 Table of Contents Why we need this Guideline... 3 What
More informationManaging Behavioural Problems in Patients with Learning Disabilities
Managing Behavioural Problems in Patients with Learning Disabilities Some people with a learning disability display behaviour that challenges. Although such behaviour is a challenge to services, family
More informationRevolutionizing Cost Management... One Person at a Time.
Cypress Care, a leader in the workers compensation industry has expanded into the auto and Medicare Set-Aside markets by applying best practices and expertise - focused toward a single goal: Help our clients
More informationDr Alex Bartle. Sleep Well Clinic
Dr Alex Bartle Sleep Well Clinic Overview of Sleep Disorders Sleep: Why bother. Effect of Poor Quality or reduced Quantity of Sleep Common Sleep Disorders Management of Insomnia Medication vs CBTi Conclusion
More information